Slim Trim Active
Slim Trim Active Price range: $ 54,00 through $ 145,00
Back to products
Snovitra
Snovitra Price range: $ 41,00 through $ 327,00

Slimonil

Price range: $ 53,00 through $ 76,00

Slimonil is designed to support individuals on their weight management journey by helping them achieve sustainable health goals. This medication works by targeting specific metabolic processes to assist in reducing excess body weight effectively. It provides a reliable option for those looking to manage clinical obesity and improve their overall physical well-being. The specialized formula helps maintain a balanced metabolic rate while supporting consistent weight control over time. Incorporate Slimonil into your daily wellness routine to enhance your progress and reach your desired fitness results.

SKU: Slimonil Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Slimonil belongs to the pharmacologic class of centrally acting serotonin-norepinephrine reuptake inhibitors (SNRIs) evaluated for therapeutic weight management. Prescribed as an adjunct to a reduced-calorie diet and structured physical activity, the active substance acts primarily on central neurochemical pathways to regulate appetite and increase postprandial satiety.

In the United States, pharmaceutical agents in this pharmacological category are dispensed in accordance with applicable federal and state regulations under appropriate medical supervision. Baseline medical evaluation, including cardiovascular screening and baseline blood pressure assessment, is required prior to initiating therapy with Slimonil.

Drug Name Slimonil
Active Ingredient (INN) Sibutramine hydrochloride
Primary Purpose Weight management in therapeutic care
Dosage Form Oral capsule
Route of Administration Oral
Storage Room temperature (68°F to 77°F)

Product Overview and Mechanism of Action

How the drug works

Sibutramine hydrochloride, the active component of Slimonil, produces its pharmacological effect through the inhibition of monoamine reuptake. It predominantly inhibits the reuptake of norepinephrine and serotonin (5-HT), while exerting a minor effect on dopamine reuptake. Unlike classical amphetamine-like anorectics, the drug does not stimulate the release of monoamines into the synaptic cleft. The primary metabolite derivatives, secondary amine (M1) and primary amine (M2), are the pharmacologically active moieties responsible for the central appetite-suppressing activity. By blocking monoamine reuptake in the hypothalamus, Slimonil increases the feeling of fullness during meals and reduces overall caloric intake. Additionally, clinical and pharmacological evaluations indicate that enhancement of central noradrenergic transmission may assist in attenuating the decrease in basal metabolic rate typically observed during calorie-restricted weight reduction.

What it’s used for

Slimonil is indicated for the management of obesity, including weight loss and maintenance of weight loss, when used in conjunction with a reduced-calorie diet. Clinical indications restrict its consideration to patients with an initial body mass index (BMI) of 30 kg/m² or greater, or patients with a BMI of 27 kg/m² or greater who present with concomitant risk factors such as controlled hypertension, type 2 diabetes mellitus, or dyslipidemia. Therapeutic intervention aims to reduce cardiovascular and metabolic risks associated with excess adiposity. Treatment efficacy is evaluated periodically by measuring net body weight loss over specified intervals. If a patient does not achieve adequate weight reduction after the initial treatment period, healthcare providers reassess the clinical utility and rationale of continuing therapy.

What happens in the body

Following oral administration, Slimonil is rapidly absorbed from the gastrointestinal tract, achieving peak plasma concentration (Tmax) of the parent compound within approximately 1.2 hours. Sibutramine undergoes extensive first-pass hepatic metabolism by the cytochrome P450 3A4 (CYP3A4) isoenzyme, converting it into active metabolites M1 and M2. Peak plasma concentrations of these active metabolites are attained within 3 to 4 hours post-ingestion. Systemic bioavailability of the active metabolites is approximately 77%. Absolute bioavailability of the unchanged parent drug is low due to extensive hepatic clearance. The active metabolites bind extensively to human plasma proteins (approximately 97%). Elimination occurs predominantly through hepatic metabolism followed by renal excretion of inactive conjugated metabolites. The elimination half-life of metabolite M1 is approximately 14 hours, whereas metabolite M2 exhibits a half-life of approximately 16 hours, supporting a once-daily dosing schedule.

Dosing schedule

The recommended starting dose for Slimonil is typically 10 mg administered once daily in the morning. The oral capsule should be swallowed whole with water, with or without food. If weight loss is inadequate after 4 weeks of continuous therapy at 10 mg daily, clinicians may evaluate patient tolerance and consider titrating the daily dose up to a maximum of 15 mg once daily. Doses exceeding 15 mg daily are not recommended due to increased risks of systemic adverse effects, particularly elevations in blood pressure and heart rate. For patients who exhibit sensitivity or mild tolerability issues, an initial dose of 5 mg daily may be utilized. Periodic monitoring of resting blood pressure and pulse rate is mandatory during initial dose selection and throughout the treatment course.

Clinical Considerations and Patient Safety

Compatibility with other medicines

Slimonil exhibits critical drug interactions that mandate thorough clinical review prior to co-administration. Concomitant use with monoamine oxidase inhibitors (MAOIs) or administration within 14 days of discontinuing an MAOI is strictly contraindicated due to the severe risk of serotonin syndrome, characterized by hyperthermia, neuromuscular agitation, and autonomic instability. Concurrent administration with other serotonergic agents–including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), triptans, or tramadol–significantly raises the risk of serotonergic toxicity. Because Slimonil is metabolized by CYP3A4, concurrent use of strong CYP3A4 inhibitors (such as ketoconazole, erythromycin, or clarithromycin) can elevate plasma concentrations of active metabolites M1 and M2, increasing toxicity. Conversely, CYP3A4 inducers like rifampin or carbamazepine may reduce therapeutic efficacy. Furthermore, caution is required when combining Slimonil with agents that increase blood pressure or heart rate, such as decongestants containing pseudoephedrine.

Adverse reactions

Adverse reactions associated with Slimonil primarily reflect its noradrenergic and serotonergic pharmacological profile. The most common mild-to-moderate side effects reported in clinical evaluation include dry mouth (xerostomia), insomnia, constipation, headache, and dizziness. Cardiovascular side effects represent a principal clinical concern: treatment can cause mean increases in resting heart rate of 3 to 6 beats per minute and mean elevations in systolic and diastolic blood pressure of 1 to 3 mmHg. In a subset of patients, more pronounced hemodynamic increases occur. Gastrointestinal symptoms such as nausea, altered taste perception (dysgeusia), and dyspepsia are also observed. Central nervous system reactions may include anxiety, restlessness, tremor, or nervousness. Patients experiencing persistent or bothersome side effects should consult their healthcare provider to determine whether dosage adjustment or discontinuation is warranted.

Important precautions

Slimonil carries major precautions regarding cardiovascular health. It is contraindicated in patients with a history of coronary artery disease, congestive heart failure, cardiac arrhythmias, stroke, or uncontrolled hypertension. Regular monitoring of blood pressure and heart rate is necessary for all treated individuals; sustained elevations mandate dose reduction or therapy cessation. Safety and effectiveness have not been established in pediatric patients under 16 years of age, and use is generally not recommended in elderly patients over 65 years due to decreased renal and hepatic functional reserve. Slimonil is classified as Pregnancy Category C; adequate and well-controlled studies in pregnant women are lacking, and it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing mothers should avoid use as it is unknown whether active metabolites pass into human breast milk.

What to avoid while taking it

Slimonil may be taken without regard to meal timing, as food intake does not significantly alter the total bioavailability (AUC) of active metabolites, although peak concentration times may be slightly delayed. However, patients should avoid excessive alcohol consumption while taking Slimonil. Alcohol can exacerbate central nervous system side effects such as dizziness, impaired coordination, and sedation. Additionally, acute alcohol ingestion may alter blood pressure dynamics and compromise overall compliance with dietary weight management programs. Patients are advised to discuss their alcohol intake habits with a qualified healthcare provider.

If you skip a dose

If a daily dose of Slimonil is missed, the patient should skip the missed capsule and resume the regular dosing schedule the following morning. Double doses should never be taken to compensate for a missed capsule, as taking extra medication increases the likelihood of acute cardiovascular side effects, including tachycardia and sudden blood pressure spikes. Maintaining a consistent daily routine, such as taking the dose at breakfast, helps prevent missed doses and supports steady therapeutic plasma levels of active metabolites.

Storage and expiration

Slimonil capsules should be stored at controlled room temperature, between 68°F and 77°F (20°C to 25°C), with permitted excursions between 59°F and 86°F (15°C to 30°C). The container must be kept tightly closed to protect the contents from moisture, excessive heat, and direct light exposure. Store out of reach of children and pets. Do not use capsules past the expiration date printed on the original packaging. Unused or expired medication should be disposed of properly through pharmacy take-back programs or in accordance with federal and local environmental guidelines.

Red flags

Immediate emergency medical evaluation is necessary if a patient experiences signs of severe cardiovascular or systemic complications. Emergency red flags include acute chest pain, tightness, or pressure; severe shortness of breath (dyspnea); sudden weakness or numbness in the face, arm, or leg; sudden speech impairment; or rapid, irregular heartbeats (palpitations). Symptoms suggestive of serotonin syndrome–such as high fever, severe confusion, muscle rigidity, shivering, and rapid blood pressure fluctuations–also require immediate medical intervention. Any signs of an allergic reaction, including swelling of the lips, tongue, or throat, or widespread rash, warrant immediate care.

Common questions

How frequently should blood pressure be monitored while taking Slimonil?

Blood pressure and pulse rate should be measured prior to initiating therapy and monitored at regular intervals during treatment. Typically, measurements are performed every 2 weeks during the first 2 months of therapy, and monthly thereafter. If persistent increases in resting heart rate or blood pressure occur, dosage adjustments or drug discontinuation may be indicated.

What happens if Slimonil does not produce significant weight loss after 4 to 8 weeks?

If a patient fails to lose at least 4 pounds (or approximately 5% of initial body weight) after 4 to 8 weeks of continuous treatment at an adequate dose, the clinician will reassess the overall treatment plan. Weight loss response varies by individual, and lack of response typically indicates that continuing the medication may not yield meaningful clinical benefit.

Can Slimonil be safely combined with over-the-counter weight loss supplements?

Combining Slimonil with non-prescription dietary supplements or appetite suppressants is not recommended. Many over-the-counter weight loss products contain sympathomimetic stimulants or herbal compounds that can interact unpredictably with active metabolites, increasing the risk of hypertension, arrhythmias, or neurotoxicity.

Is it safe to operate heavy machinery or drive while taking Slimonil?

Slimonil can affect central nervous system function, potentially causing dizziness, somnolence, or altered concentration in some patients. Individuals initiating therapy should assess how the medication affects their alertness before driving or operating hazardous machinery.

How does food intake impact the absorption and efficacy of Slimonil?

Food does not significantly alter the overall extent of absorption (AUC) of active metabolites M1 and M2. Consequently, Slimonil can be taken with or without meals. However, taking the capsule with a light morning meal may help minimize transient stomach discomfort or nausea.

What should be done if treatment with Slimonil needs to be stopped?

Discontinuation should be managed under medical guidance. While Slimonil is not classified as producing physical dependence in the manner of classic stimulants, abrupt cessation should be discussed with a provider to transition smoothly back to diet- and exercise-only management strategies.

In accordance with FDA requirements.

Information on this page is for reference and does not replace an assessment by a licensed healthcare professional.

Additional information
Dosage

500 mg

Package

60 caps

,

120 caps

,

180 caps

Ενεργός Ουσία

,

,

,

,

,